<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772564</url>
  </required_header>
  <id_info>
    <org_study_id>Ator2685Hdm2[2]</org_study_id>
    <nct_id>NCT00772564</nct_id>
  </id_info>
  <brief_title>The Use of Statins for Myocardial Death Prevention</brief_title>
  <official_title>The Use of Statins for Myocardial Death Prevention: From Cell to Bedside</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute
      ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/
      reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection
      fraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart EcoCardiography and specific laboratory tests</measure>
    <time_frame>Base line, second day and 60 days after myocardial infarction</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Oral Atorvastatin</description>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip
        Classification 1 and 2 will be included at-random to either group. Included subjects should
        be able to give their informed consent to participate in this study.

        Exclusion Criteria:

          1. The impossibility to give the required informed consent.

          2. Known allergy to Atorvastatin.

          3. Base line serum creatinine of 1.4 mg/dL.

          4. Killip Classification 3 and 4.

          5. Persisting vomiting.

          6. History of previous liver disease.

          7. History of previous muscle disease or rabdomyolisis.

          8. Treated already with high dose atorvastatin

          9. Non Compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sammer Diab, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>N_Krivoy</investigator_full_name>
    <investigator_title>Clinical Pharmacology Unit</investigator_title>
  </responsible_party>
  <keyword>Acute ST Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

